Biography
Rob is the CEO of Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company pursuing drug therapies for Multiple Sclerosis, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease). Clene’s first drug, CNM-Au8, has presently completed multiple Phase 2 clinical human trials for remyelination in multiple sclerosis patients, and neurodegeneration for Parkinson’s and ALS, as well as a registration (Phase 3) study for ALS, with its ALS program presently in front of the FDA. A pipeline of other therapeutic nanotherapeutics is presently in preclinical development.
As CEO of Clene Nanomedicine, Rob has raised over $200M to fund Clene’s drug development efforts. Clene went public on NASDAQ in late 2021.
Rob has more than 30 years of leadership experience in the pharmaceutical industry. Before joining the company as CEO, Mr. Etherington worked for Actelion Pharmaceuticals, which was the largest biopharmaceutical company based in the EU until it was acquired by Johnson & Johnson in 2017. He initially joined Actelion as the founding Director of Marketing in 2000, the same year the company went public, and went on to hold various roles of increasing responsibility, where he was responsible for five marketed drugs. Before joining Actelion, Mr. Etherington began his pharmaceutical career with several sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position that oversaw the development ofthe drug Uptior.
Rob has seven daughters, 21 grandchildren, and serves with his wife, Linda, as Chair of the BYU Life Sciences Leadership Council.
Membership Information
Member since: 10/01/2024
Current Role: Executive Chair
Spouse
Contact Information
LinkedIn Profile: https://www.linkedin.com/in/rob-etherington-431718/
Expertise
- Pharmeceutical
- Biotechnology
Education
- BA History - BYU
- MBA - BYU
- Harvard Business School Graduate Management Program
Employment
Job Title: CEO/President
Company: Clene Nanomedicine
Location: Salt Lake City, Utah